| Feature Type | Standardized | Nominal ANOVA | ||||
|---|---|---|---|---|---|---|
| mRNA | Vandetanib | FIMM | pan-cancer | AAC | -0.17 | 0.3 |
| mRNA | CIL55A | CTRPv2 | pan-cancer | AAC | -0.048 | 0.3 |
| mRNA | GSK1070916 | GDSC1000 | pan-cancer | AAC | 0.031 | 0.3 |
| mRNA | BRD-K02492147 | CTRPv2 | pan-cancer | AAC | 0.038 | 0.3 |
| mRNA | GSK-1904529A | GDSC1000 | pan-cancer | AAC | -0.032 | 0.3 |
| mRNA | FR-180204 | GDSC1000 | pan-cancer | AAC | -0.033 | 0.4 |
| mRNA | thalidomide | CTRPv2 | pan-cancer | AAC | -0.053 | 0.4 |
| mRNA | SGX-523 | CTRPv2 | pan-cancer | AAC | -0.034 | 0.4 |
| mRNA | paclitaxel | FIMM | pan-cancer | AAC | 0.13 | 0.4 |
| mRNA | S-Trityl-L-cysteine | GDSC1000 | pan-cancer | AAC | 0.051 | 0.4 |